Novo Nordisk A/s Stock News

Novo Nordisk's (NVO) earnings and revenues beat estimates in Q4. Sales are driven by growth in Diabetes and Obesity Care on higher GLP-1 revenues.

Novo Nordisk A/S (NVO) CEO Lars Jorgensen on Q4 2021 Results - Earnings Call Transcript

Novo Nordisk A/S NVO reported Q4 sales of DKK 38.3 billion, up 19% Y/Y on a reported basis and 16% on constant exchange rates (CER). Thousands of new traders are learning the ins and outs on how to

Novo Nordisk press release (NVO): Q4 GAAP EPS of DKK4.76.Revenue of DKK38.33B (+19.3% Y/Y).Gross margin of 83.7%; Operating margin of 35.6%.For 2022, sales growth is expected to be 6%

Danish drug developer Novo Nordisk posted on Wednesday fourth quarter operating profit that was below expectations, and said it expected to generate sales growth in local currencies of between 6% and

Let us take a look at three large pharma companies - ABBV, NVS and NVO - due to release their quarterly results on Feb 2.

Key Events This Week: ECB, BOE, Payrolls, Euro CPI And Earnings Galore It''s a relatively busy week with several key central bank announcements, notably from the ECB and BOE, as well as European CPI updates and the US payrolls report on Friday. Starting with the ECB, Deutsche Bank economists now expect a policy rate liftoff in December 2022 of 25bps, a view apparently shared by the market this morning. Theyre also anticipating a faster pace of tightening, with 25bp hikes in the deposit rate per quarter from December 2022, until rates reach +0.5% in September 2023. In terms of what it means for this February meeting, they write in their preview that they expect the slow, step-by-step pivot to exit will continue. Their view is that President Lagarde will reiterate the ECBs capacity to act once the inflation criteria in the rates guidance are met, whilst at the same time differentiating the needs of the Euro Area from the US. The other central bank decision that day is from the Bank of England, where expectations are for the BoE to follow up their December rate hike with another 25bps increase, taking the Bank Rate to 0.5%.

US Futures Start The Week With More Wild Swing In Another Volatile, Illiquid Session After a rollercoaster week that ended just barely higher following a late meltup on Friday, overnight volatile US stock futures swung to start the week, with Nasdaq 100 futures leading gains after rallying on Friday, before turning red and threatening to fizzle a global equity rally amid persistent worries over the Federal Reserve’s plan to hike interest rates this year. Emini S&P futures were down 0.5% or 21 points to 4401, after rising as high as 4437 and dropping as low as 4395 in another extremely illiquid session where China being offline for the week due to Lunar New Year did not help; Nasdaq futures were down 0.1% while Dow futures were lower 0.7%. Technology stocks led gains on the Stoxx Europe 600. Meanwhile, the dollar fell and oil rallied. As investors reconcile to a hawkish U.S. central bank coupled with strong earnings, the expensive parts of the U.S. stock market are undergoing a valuation re-rating along with the bond markets.

NVO has increased their market share more rapidly than the overall market growth for diabetes treatment.

Last week, Catalent Inc (NYSE: CTLT) received an FDA write-up for its syringe filling facility in Belgium, "allegedly" the culprit behind supply shortage for Novo Nordisk A/S's (NYSE: NVO) obesity

Eagle Ridge Investment Management bought a new position in shares of Novo Nordisk A/S (NYSE:NVO) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 2,240 shares of the company’s stock, valued at approximately $215,000. A number of other institutional investors and hedge funds have […]

Banque Cantonale Vaudoise lessened its position in Novo Nordisk A/S (NYSE:NVO) by 5.0% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,523 shares of the companys stock after selling 132 shares during the period. Banque Cantonale Vaudoises holdings in Novo Nordisk []

Citigroup downgraded shares of Novo Nordisk A/S (NYSE:NVO) from a buy rating to a neutral rating in a research note released on Monday, The Fly reports. Several other equities analysts have also recently issued reports on the stock. JPMorgan Chase & Co. cut shares of Novo Nordisk A/S from an overweight rating to a neutral []